1.Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer.
Claudia MARCHETTI ; Francesca DE FELICE ; Anna DI PINTO ; Alessia ROMITO ; Angela MUSELLA ; Innocenza PALAIA ; Marco MONTI ; Vincenzo TOMBOLIN ; Ludovico MUZII ; PierLuigi BENEDETTI PANICI
Cancer Research and Treatment 2018;50(3):768-776
PURPOSE: The purpose of this study was to develop nomograms for predicting the probability of overall survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical surgery. MATERIALS AND METHODS: Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Calibration plots were constructed, and concordance indices were calculated. Evaluated variableswere body mass index, age, tumor size, tumor histology, grading, lymphovascular space invasion, positive parametria, and positive lymph nodes. RESULTS: In total 245 patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical surgery were included for the construction of the nomogram. The 5-year OS and PFS were 72.6% and 66%, respectively. Tumor size, grading, and parametria status affected the rate of OS, whereas tumor size and positive parametria were the main independent PFS prognostic factors. CONCLUSION: We constructed a nomogram based on clinicopathological features in order to predict 2-year PFS and 5-year OS in locally advanced cervical cancer primarily treated with neoadjuvant chemotherapy followed by radical surgery. This tool might be particularly helpful for assisting in the follow-up of cervical cancer patients who have not undergone concurrent chemoradiotherapy.
Body Mass Index
;
Calibration
;
Chemoradiotherapy
;
Disease-Free Survival
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Lymph Nodes
;
Nomograms*
;
Recurrence
;
Uterine Cervical Neoplasms*
2.Comparison of Anogenital Distance and Correlation with Vulvo-vaginal Atrophy: A Pilot Study on Premenopausal and Postmenopausal Women
Lavinia DOMENICI ; Angela MUSELLA ; Carlotta BRACCHI ; Francesca LECCE ; Michele Carlo SCHIAVI ; Vanessa COLAGIOVANNI ; Violante DI DONATO ; Claudia MARCHETTI ; Federica TOMAO ; Innocenza PALAIA ; Ludovico MUZII ; Pierluigi BENEDETTI PANICI
Journal of Menopausal Medicine 2018;24(2):108-112
OBJECTIVES: Anogenital distance (AGD) represents the space between labia posterior commissure and anus. This was pilot study to investigate how menopause and so lack of oestrogens affects AGD. METHODS: A total of 109 patients were enrolled. AGD was measured in lithotomy position using sterile paper ruler. Anogenital index (AGI) was used to control 2 variables of height and weight (body mass index, kg/m2). Vaginal health index (VHI) was used to evaluate vaginal wellness. Female sexual function index (FSFI) questionnaire was administered to all women to evaluate the impact of menopause on their sexual function. RESULTS: AGD (30.87 ± 2.98 vs. 17.57 ± 2.18; P = 0.0001) and AGI (1.40 ± 0.21 vs. 0.70 ± 0.15; P = 0.0001) were both significantly lower in the postmenopausal group. Postmenopausal women were affected by vulvovaginal atrophy (VVA) significantly. Thus, VHI scores were dramatically worse in postmenopausal group (23.95 ± 1.28 vs. 10.75 ± 3.41; P = 0.0001) as well as FSFI results (32.68 ± 2.25 vs. 19.78 ± 5.46; P = 0.0001). CONCLUSIONS: This study confirms that AGD in post-menopausal women was significantly shorter than AGD in premenopausal women, correlating with an increase of VVA and sexual impairment. Changes of AGD and AGI demonstrated to predict hormonal changes that may occur after menopause.
Anal Canal
;
Atrophy
;
Female
;
Humans
;
Menopause
;
Pilot Projects
;
Sexuality
3.ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
Giulia AMADIO ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2020;31(1):6-
1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.CONCLUSIONS: Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.]]>
Aged
;
Bevacizumab
;
Case-Control Studies
;
Comorbidity
;
Creatinine
;
Diagnosis
;
Drug Therapy
;
Female
;
Glomerular Filtration Rate
;
Humans
;
Logistic Models
;
Ovarian Neoplasms
4.ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
Giulia AMADIO ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2020;31(1):e6-
Objective:
Bevacizumab maintenance following platinum-based chemotherapy is an effective treatment for epithelial ovarian cancer (EOC), both in primary and recurrent disease. Our aim was to identify criteria to select elderly patients who can safely benefit from bevacizumab addition.
Methods:
This is a case-control study on patients with primary or recurrent EOC who received platinum-based chemotherapy plus bevacizumab, between January 2015 and December 2016. Patient characteristics, treatment details and adverse events were reviewed and analyzed in 2 settings: younger (<65 years, group 1) and elderly (≥65 years, group 2). A binary logistic model was applied to correlate clinical variables and severe (grade ≥3) toxicity risk.
Results:
Overall, 283 patients with EOC were included, with 72 (25.4%) older patients compared with 211 (74.6%) younger women. Bevacizumab had been administered to 234 patients (82.7%) as first-line treatment and in 49 (17.3%) with recurrent disease. At diagnosis, elderly patients presented with at least one comorbidity and were taking at least 1 medication in 84.7% and 80.6% of the cases respectively, compared with correspondingly 47.4% and 37.4% in group 1 (p<0.001). Nonetheless, the occurrence of serious (grade ≥3) adverse events did not increase among the older group. Creatinine serum levels >1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.
Conclusions
Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.